CVHealthcare · Medical DevicesThe 1 Wall Street analysts covering CapsoVision, Inc. hold a median 12-month price target of $10 — +39.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CapsoVision, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (61): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own CapsoVision, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +39.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Mar 2026 | Benchmark | Maintains | Speculative Buy | $14 → $10 |
| 31 Dec 2025 | Benchmark | Maintains | Speculative Buy | — |
| 28 July 2025 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 8% of US stocks
Cheaper than 6% of US stocks
Cheaper than 85% of US stocks
Higher than 30% of US stocks
Higher than 61% of US stocks
Higher than 10% of US stocks
Higher than 2% of US stocks
Higher than 7% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CV appears on the weeks it earns a place.
CapsoVision announced the international launch of its AI Highlights feature, an AI-assisted review tool designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus system.
Why it matters — The international rollout of an AI-assisted review feature expands the capabilities of CapsoVision's CapsoCam Plus product in the capsule endoscopy market.
CapsoVision announced it will release its second quarter 2026 financial results on August 13, 2026, after market close. The company develops advanced imaging and AI-enabled capsule endoscopy solutions.
Why it matters — This is a standard earnings release announcement that will provide the latest financial performance data for CapsoVision.
The 1 Wall Street analysts covering CapsoVision, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering CapsoVision, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CapsoVision, Inc. 18 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, CapsoVision, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (61 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +39.5% from the last close, and Ticker Nerd's factor model ranks CapsoVision, Inc. 18 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CapsoVision, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
CapsoVision, Inc. returned +83.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
CapsoVision, Inc. is a commercial-stage medical technology company specializing in advanced imaging and artificial intelligence technologies for endoscopy solutions.
The most recent item we track (GlobeNewsWire, 3 Aug 2026): "CapsoVision® Announces International Launch of AI Highlights". CapsoVision announced the international launch of its AI Highlights feature, an AI-assisted review tool designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus system.
CapsoVision, Inc. is a commercial-stage medical technology company specializing in advanced imaging and artificial intelligence technologies for endoscopy solutions. It focuses on identifying abnormalities in the gastrointestinal tract for diagnostic and screening purposes. The company's core product is the CapsoCam Plus, a single-use capsule endoscope system that provides panoramic visualization of the small-bowel mucosa to detect conditions such as obscure gastrointestinal bleeding and Crohn's disease. Additional offerings include CapsoCam Colon for colon visualization, polyp detection, and measurement, along with CapsoCloud, a cloud-based software-as-a-service platform for video access and download; CapsoAccess for capsule data management; CapsoView for video reading; and CapsoRetrieve, a retrieval kit using a magnetic wand. CapsoVision also provides capsule video reading services. These solutions serve gastrointestinal medical practices, clinics, and hospitals through distributor customers who resell the products. Founded in 2005 and headquartered in Saratoga, California, CapsoVision plays a key role in enhancing non-invasive diagnostic capabilities within the health technology sector.
CEO Mr. Kang-Huai Wang · 99 employees · United States · https://capsovision.com